CABALETTA BIO INC (CABA)
Health Care · biotechnology · NASDAQ
Cabaletta Bio is a clinical-stage biotechnology company developing CARTA engineered T cell therapies intended to provide durable, potentially curative, one-time treatments for patients with a wide range of autoimmune diseases.
What CABALETTA BIO INC does
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies to treat autoimmune diseases. Its proprietary CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) platform is designed to reset the immune system by performing deep, transient B cell depletion using its lead product candidate, rese-cel. The company is evaluating these therapies across rheumatology, neurology, and dermatology indications.
Recent developments
In August 2026, the company announced the selection of ElevateBio as a second CDMO for manufacturing. It is also advancing a registrational study for SSc-associated interstitial lung disease expected to start in 4Q26 and is incorporating a preconditioning-free approach into its RESET-MG trial.
From CABALETTA BIO INC's filing of 2026-08-13.
Themes: autoimmune diseases, cell therapy, CAR-T, lupus, myositis, systemic sclerosis, B cell depletion
Fundamentals
- Price$1.95 as of 2026-10-08 close
- Market cap$331M as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return-19.1% 2025-10-08 close $2.41 → 2026-10-08 close $1.95
- P/En/a negative earnings
- ROE-149.8% FY2025, SEC XBRL
- Debt / equity0.23 as of 2026-09-03
- Beta1.79 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CABA compares in its sector
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CABALETTA BIO INC looks technically
CABALETTA BIO INC (CABA) is trading 32.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 17 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago. It is 53.9% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 32.6% below its 200-day average, the long-term trend line — a long-term downtrend | -32.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.70 | $2.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.89 | $2.89 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 35 calendar days ago — the swings before that are what the structure reading is measured on | 35 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 17 trading days ago — a "death cross", a bearish long-term signal | 17 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control | 33.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30) | 32.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($1.83 to $2.65) — its "stochastic" reading is 15 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 14.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.23 | $4.23 |
|---|---|---|
| From the 52-week high | it is 53.9% below its 52-week high (its highest price of the past year) | -53.9% |
| Above the 52-week low | it is 6.6% above its 52-week low (its lowest price of the past year) | +6.6% |
| Below the 52-week high | it is 53.9% below its highest point of the past year | 53.9% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $26.35 (set on 2024-02-08) | $26.35 |
| Given back of the 52-week move | over the past year its closes ranged ($1.89 to $4.15), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.29 to $3.36. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.6% |
| From the all-time high | it is 92.6% below its all-time high | -92.6% |
| Nearest price level | it is trading 2.9% below a resistance level at $2.01 — a price it turned at three times since 2025-03-12, most recently on 2026-01-06. Since 2024-10-08 it has 2 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.9% |
| All-time low | its lowest closing price on record is $0.59 (set on 2022-09-23) | $0.59 |
| Above the all-time low | it is 230.5% above its all-time low | +230.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 91% of the past ~6 months) | 91st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1718 between its high and its low — about 8.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1718 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.64 and $2.87 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.64 – $2.25 – $2.87 |
| Typical daily range (% of price) | its price moves about 8.8% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.8% |
| Stretch from the 200-day average | it is trading 5.5 daily ranges below its 200-day average price (32.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.04× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 2.7% gap up opened on 2026-10-02 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -6.25% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 41.4 percentage points (the stock lost 40.4% while the market gained 1.0%) | -41.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 41.5 percentage points (the stock lost 37.7% while the market gained 3.8%) | -41.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 52.7 percentage points (the stock lost 35.2% while the market gained 17.5%) | -52.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 34.1 percentage points (the stock lost 19.1% while the market gained 15.0%) | -34.1% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 35% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.2% of the share price. | -35.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 34% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.97 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -34.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 27% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.68 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -27.2% |
Price levels it has turned at before
CABA last closed at $1.95 on 2026-10-08. Since 2024-10-08 it has turned at 2 prices below its last close and 8 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.01 | Resistance | 2.9% above the last close | turned there three times · 2025-03-12 to 2026-01-06 |
| $1.75 | Support | 10.3% below the last close | turned there twice · 2024-11-21 to 2025-07-28 |
| $2.16 | Resistance | 10.6% above the last close | turned there three times · 2024-12-19 to 2025-05-16 |
| $1.40 | Support | 28.2% below the last close | turned there three times · 2025-04-23 to 2025-08-29 |
| $2.59 | Resistance | 32.8% above the last close | turned there three times · 2025-06-09 to 2026-08-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$13.25 range $3.00 – $30.00; median $13.50
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CABA
- Consensus EPS estimate-$0.3059 next reporting period, as of 2026-10-07
- Estimate change, 30 days$0.00 from -$0.3059, on 2026-09-02, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in early clinical development and has not yet received regulatory approval for any product, leading to uncertainty regarding potential commercialization.","Dependency on the successful clinical outcomes of the CARTA platform and the lead candidate rese-cel to generate revenue.","Reliance on third-party contract manufacturing organizations (CDMOs) for clinical and commercial supply."]
What changed in the latest 10-Q
AI-assisted comparison of CABA's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-13) adds description of presentations at EULAR 2026 Congress (June 2026) including data from 52 evaluable autoimmune disease patients with myositis (17), lupus (20), and systemic sclerosis (15) treated with rese-cel.
- Newer filing (2026-08-13) adds mention of the first juvenile dermatomyositis (JDM) patient and the first two lupus patients treated with PC-free rese-cel.
- Newer filing (2026-08-13) adds statement that rese-cel exhibited a predictable translational profile when administered with and without PC, consistent across each indication evaluated.
- Newer filing (2026-08-13) adds statement that patients were generally able to discontinue all immunomodulators and require no or only low-doses of steroids while achieving significant improvement in disease activity following rese-cel treatment.
- Newer filing (2026-08-13) adds updated safety data from the first 63 patients treated with rese-cel with PC across four RESET trials reported at EULAR.
- Newer filing (2026-08-13) adds description of pan-translational findings presented at EULAR highlighting PK/PD dynamics showing short-term rese-cel activity phase, deep B cell depletion and immune system reset, and B cell repopulation with median time of approximately 2 months.
- Newer filing (2026-08-13) adds statement about planning for a pediatric submission in JDM and that this strategy may allow the Company to receive a priority review voucher because rese-cel has Rare Pediatric Disease Designation for JDM.
- Newer filing (2026-08-13) adds statement that the pediatric submission relates to JDM specifically (previously had stated JIIM).
- Removed:
- Older filing (2026-05-14) describes efficacy and safety of rese-cel reviewed in a February 2026 Nature Biotechnology publication, along with all other commercial and academic constructs in development.
- Older filing (2026-05-14) includes safety data as of December 2025 for the first 40 patients dosed with rese-cel with preconditioning across four RESET trials: 95% had no CRS or Grade 1 CRS (transient fever) and 95% experienced no ICANS.
- Older filing (2026-05-14) states that in December 2025, the Company initiated a registrational trial with rese-cel for patients with dermatomyositis or anti-synthetase syndrome.
- Older filing (2026-05-14) describes ongoing Phase 1/2 trials evaluating rese-cel with standard preconditioning (fludarabine and cyclophosphamide) in SLE, LN, SSc, and gMG.
- Older filing (2026-05-14) describes evaluating rese-cel without preconditioning in non-renal SLE and LN patients, and that longer-term data from no-preconditioning SLE, LN and PV patients is expected in the second half of 2026.
- Older filing (2026-05-14) describes January 2026 IND clearance for rese-cel manufactured using the Cellares Cell Shuttle automated manufacturing platform.
- Older filing (2026-05-14) describes April 2026 commercial supply agreement with Cellares for commercial supply of rese-cel using the automated Cell Shuttle and future implementation of Cellares' Cell Q platform.
- Reworded:
- Older filing (2026-05-14) describes the company as a 'late clinical-stage biotechnology company'; newer filing (2026-08-13) describes it as a 'late-stage clinical biotechnology company'.
- Older filing (2026-05-14) phrases the CABA platform description as 'the CARTA, or Chimeric Antigen Receptor T cells for Autoimmunity, approach'; newer filing (2026-08-13) phrases it as 'the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach'.
- Older filing (2026-05-14) uses parentheses for 'rese-cel, formerly referred to as CABA-201'; newer filing (2026-08-13) uses 'formerly referred to as CABA-201' without parentheses.
- Older filing (2026-05-14) states pediatric submission planned in 'juvenile idiopathic inflammatory myopathy, or JIIM'; newer filing (2026-08-13) states pediatric submission planned in JDM.
- Older filing (2026-05-14) writes 'American College of Rheumatology, or ACR, Convergence 2025'; newer filing (2026-08-13) writes 'American College of Rheumatology (ACR) Convergence 2025'.
- Older filing (2026-05-14) abbreviates 'Total Improvement Score' as 'TIS' without expanding first; newer filing (2026-08-13) expands as 'Total Improvement Score (TIS)'.
- Older filing (2026-05-14) states 'Ph 1/2 cohort'; newer filing (2026-08-13) states 'Phase 1/2 cohort'.
- Older filing (2026-05-14) spells out FDA as 'U.S. Food and Drug Administration' parenthetically at first use of FDA; newer filing (2026-08-13) states 'the U.S. Food and Drug Administration (FDA)'.
- Notes:
- The newer filing text appears truncated in the provided excerpt (ends mid-sentence about the registrational cohort).
- The older filing text also appears truncated in the provided excerpt (ends mid-sentence about the background rate).
- Only the MD&A section excerpts were compared, so changes in other sections are not assessed.
- Both texts contain page number references that appear to be formatting artifacts.
Risk Factors
- Notes:
- The provided excerpts of the newer and older Risk Factors sections are substantially identical; the only visible difference is the page number (38 in the newer filing vs. 36 in the older filing).
- Both excerpts end mid-sentence at the same point ('...support our clinical trials, and, i'), so any changes beyond the truncated portion cannot be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Most recent open-market transaction: 2026-01-21. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CABA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CABA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 28,410,858
- Reported value $88,357,769
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CABA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CABA had 33,325,453 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CABA had 19.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.2 days to cover at the same settlement.
- Reported short interest (shares) 33,325,453
- Short interest (% of shares outstanding) 19.7%
- Prior settlement (shares) 41,442,251
- Reported change -19.59%
- Days to cover (reported) 5.2
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
- Gilead Sciences (GILD)
- Kyverna Therapeutics (KYTX)
- Cartesian Therapeutics (RNAC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CABA vs…
CABALETTA BIO INC is found in…
Frequently asked questions
What does CABALETTA BIO INC (CABA) do?
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies to treat autoimmune diseases. Its proprietary CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) platform is designed to reset the immune system by performing deep, transient B cell depletion using its lead product candidate, rese-cel. The company is evaluating these therapies across rheumatology, neurology, and dermatology indications.
What sector is CABALETTA BIO INC (CABA) in?
CABALETTA BIO INC (CABA) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CABALETTA BIO INC's (CABA) competitors?
Notable peers of CABALETTA BIO INC (CABA) include Bristol Myers Squibb, Novartis, Gilead Sciences, Kyverna Therapeutics and Cartesian Therapeutics. This peer set is informational only — not financial advice.
Is CABALETTA BIO INC (CABA) overbought or oversold right now?
CABALETTA BIO INC (CABA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 32, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CABA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.